Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Memoriam: Lawrence Crane Wood (1935-2026).

Thyroid : official journal of the American Thyroid Association·2026
Same author

Rethinking paracorporeal lung assist device support in the modern era: Why so different than ECMO?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

In Memoriam: Lawrence Crane Wood (1935-2026).

Thyroid : official journal of the American Thyroid Association·2026
Same author

Kidney and blood pressure sequelae after pediatric extracorporeal membrane oxygenation: a secondary analysis of the Kidney Injury During Membrane Oxygenation pediatric ECMO cohort.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Endocrine Effects of Arginine-Vasopressin After Pediatric Cardiac Surgery.

Pediatric cardiology·2025
Same author

Increased utilisation of analgesia and sedation in patients following bidirectional Glenn: evidence for the "Glenn Headache"?

Cardiology in the young·2025
Same journal

EDITORIAL INTRODUCTION.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Exploring the role of parathyroid hormone in sarcopenia: A review.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Normocalcemic primary hyperparathyroidism: an update on diagnostic and management challenges.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Prediabetes before pregnancy: implications for risk stratification and research.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Secondary hyperparathyroidism in chronic kidney disease: update on pathophysiology and new treatment targets.

Current opinion in endocrinology, diabetes, and obesity·2026
Same journal

Revisiting the relationship between weight loss and bone health in people living with obesity: insights from the latest evidence.

Current opinion in endocrinology, diabetes, and obesity·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Immunofluorescent Detection of Two Thymidine Analogues (CldU and IdU) in Primary Tissue
10:55

Immunofluorescent Detection of Two Thymidine Analogues (CldU and IdU) in Primary Tissue

Published on: December 7, 2010

The propylthiouracil dilemma.

Daniel Glinoer1, David S Cooper

  • 1Division of Endocrinology, Hospital Saint Pierre, University of Brussels, Brussels, Belgium. daniel.glinoer@gmail.com

Current Opinion in Endocrinology, Diabetes, and Obesity
|July 24, 2012
PubMed
Summary
This summary is machine-generated.

Propylthiouracil (PTU) is linked to severe liver damage in children and adults, especially with prolonged use. Methimazole (MMI) is recommended as a safer alternative for most hyperthyroid patients.

More Related Videos

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

Related Experiment Videos

Last Updated: May 20, 2026

Immunofluorescent Detection of Two Thymidine Analogues (CldU and IdU) in Primary Tissue
10:55

Immunofluorescent Detection of Two Thymidine Analogues (CldU and IdU) in Primary Tissue

Published on: December 7, 2010

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

Area of Science:

  • Endocrinology
  • Hepatology
  • Pharmacovigilance

Background:

  • Propylthiouracil (PTU) is an antithyroid medication used to treat hyperthyroidism.
  • Hepatotoxicity is a known, albeit rare, adverse effect associated with PTU.
  • Recent analyses highlight the need for updated clinical guidance regarding PTU use.

Purpose of the Study:

  • To re-evaluate PTU-related hepatotoxicity using FDA data (1982-2008).
  • To analyze severe liver adverse events in pediatric, adult, and pregnant patients treated with PTU.
  • To propose updated recommendations for the clinical application of PTU.

Main Methods:

  • Reanalysis of medical files reporting acute liver failure in PTU-treated patients.
  • Specific analysis of pediatric cases (13 files), nonpregnant adult cases (17 files), and pregnant cases (2 files).
  • Review of PTU dosage, treatment duration, and timing of liver injury.

Main Results:

  • High daily PTU doses (mean 300 mg/day) were observed in pediatric cases.
  • Prolonged PTU treatment (≥4 months) was common in pediatric (75%) and adult (64%) patients experiencing liver injury.
  • Liver injury in adults often occurred after extended treatment periods (4 months to over 1 year).

Conclusions:

  • PTU should be avoided in children; methimazole (MMI) is the preferred alternative.
  • In adults, PTU use should be limited to specific cases like Graves' disease without alternatives or thyroid storm.
  • During pregnancy, PTU is preferred early on, with potential switching to MMI later; the utility of liver function monitoring for preventing severe PTU hepatotoxicity remains uncertain.